Skip to content

Rituximab

Rituxan, MabThera (rituximab) is an antibody pharmaceutical. Rituximab was first approved as Rituxan on 1997-11-26. It is used to treat b-cell lymphoma, granulomatosis with polyangiitis, lymphoid leukemia, mantle-cell lymphoma, and microscopic polyangiitis amongst others in the USA. It has been approved in Europe to treat b-cell chronic lymphocytic leukemia, granulomatosis with polyangiitis, microscopic polyangiitis, non-hodgkin lymphoma, and pemphigus amongst others. The pharmaceutical is active against B-lymphocyte antigen CD20.
Trade Name MabThera
Common Name Rituximab
ChEMBL ID CHEMBL1201576
Indication b-cell chronic lymphocytic leukemia, b-cell lymphoma, granulomatosis with polyangiitis, lymphoid leukemia, mantle-cell lymphoma, microscopic polyangiitis, non-hodgkin lymphoma, pemphigus, rheumatoid arthritis
Drug Class Monoclonal antibodies: chimeric, tumors as target
Rituximab
Get full access now